Bottom line
FBDIX vs BIB: the short answer
FBDIX (Franklin Biotechnology Discovery Fund) and BIB (ProShares Ultra Nasdaq Biotechnology) are quite different portfolios: only about 32% of their top holdings (by weight) are shared.
But BIB is far broader, holding 267 positions to 126 for FBDIX, so beyond the top names it adds exposure FBDIX doesn't have.
BIB is cheaper at 0.95% vs 1.01% — a difference of $6.00 a year per $10,000 invested.
Over five years, FBDIX returned +5.0% a year vs −1.0% for BIB.
FBDIX has a front-end sales load of up to 5.5%; the other does not.
Updated Nov 19, 2026
FBDIX vs BIB side by side
| FBDIX | BIB | |
|---|---|---|
| Type | Mutual fund | ETF |
| Fund family | Franklin Templeton | ProShares |
| Category | Technology Sector | Technology Sector |
| Expense ratio | 1.01% | 0.95% |
| Annual cost per $10k | $101 | $95 |
| 10-yr cost on $10k (prospectus) | $1,728 | $1,401 |
| Max front load | 5.5% | None |
| 12b-1 fee | 0.25% | — |
| 1-yr return | +43.9% | +59.3% |
| 5-yr return (annualized) | +5.0% | −1.0% |
| 10-yr return (annualized) | +6.4% | +1.4% |
| Best quarter | +29.5% | +56.2% |
| Worst quarter | −24.5% | −42.7% |
| Net assets (fund) | $1.2B | $73.7M |
| Number of holdings | 126 | 267 |
| Portfolio turnover | 38% | 29% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | FBDIX | BIB | Difference |
|---|---|---|---|
| 2025 | +52.3% | +59.3% | −7.0% |
| 2024 | +4.0% | −10.0% | +14.0% |
| 2023 | +18.4% | −1.3% | +19.7% |
| 2022 | −12.7% | −28.6% | +16.0% |
| 2021 | −17.7% | −5.9% | −11.8% |
| 2020 | +29.9% | +39.7% | −9.8% |
| 2019 | +34.8% | +45.5% | −10.7% |
| 2018 | −15.7% | −24.4% | +8.7% |
| 2017 | +18.8% | +40.8% | −22.0% |
| 2016 | −17.2% | −44.2% | +27.1% |
Source: Fund prospectus bar charts
Holdings overlap
8 of FBDIX's top 25 holdings also appear in BIB's top 25.
| Holding | FBDIX | BIB |
|---|---|---|
| Amgen, Inc. | 4.39% | 4.48% |
| Gilead Sciences, Inc. | 3.86% | 4.66% |
| Regeneron Pharmaceuticals, Inc. | 3.77% | 3.21% |
| Argenx SE | 3.62% | 1.19% |
| Vertex Pharmaceuticals, Inc. | 3.54% | 4.65% |
| Revolution Medicines, Inc. | 3.01% | 1.57% |
| Guardant Health, Inc. | 2.76% | 0.85% |
| Insmed, Inc. | 1.99% | 1.16% |
Source: SEC Form N-PORT
FBDIX top 10
- Jazz Pharmaceuticals plc — 5.66%
- Amgen, Inc. — 4.39%
- Gilead Sciences, Inc. — 3.86%
- Regeneron Pharmaceuticals, Inc. — 3.77%
- Argenx SE — 3.62%
- Vertex Pharmaceuticals, Inc. — 3.54%
- Franklin Institutional U.S. Government Money Market Fund — 3.18%
- Revolution Medicines, Inc. — 3.01%
- Guardant Health, Inc. — 2.76%
- Ascendis Pharma A/S — 2.56%
BIB top 10
- N/a — 7.35%
- ProShares GENIUS Money Market ETF — 6.80%
- Gilead Sciences, Inc. — 4.66%
- Vertex Pharmaceuticals, Inc. — 4.65%
- Amgen, Inc. — 4.48%
- N/a — 3.94%
- N/a — 3.26%
- Regeneron Pharmaceuticals, Inc. — 3.21%
- N/a — 2.62%
- Alnylam Pharmaceuticals, Inc. — 2.01%
FAQ
What is the difference between FBDIX and BIB?
Which is cheaper, FBDIX or BIB?
Should I own both FBDIX and BIB?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.